All Posts:Parkinson's disease
-
Georgetown University Licenses Use of Tyrosine Kinase Inhibitors for Treatment of Neurodegenerative Diseases
Georgetown University today announces it has exclusively licensed worldwide intellectual property (IP) rights to develop and commercialize uses of tyrosine kinase (TK) inhibitors for the treatment of neurodegenerative diseases to Axovant Sciences GmbH.
Category: News Release
-
Steroid Originally Discovered in the Dogfish Shark Attacks Parkinson’s-Related Toxin in Animal Model
A naturally occurring steroid made by the dogfish shark prevents the buildup of a lethal protein in animal studies, reports an international team of researchers. The clustering of this protein, alpha-synuclein (α-synuclein), is the hallmark of Parkinson’s disease and dementia with Lewy bodies, suggesting a new potential compound for therapeutic research.
Category: News Release
-
Nobel Prize-winning Science is Key to Georgetown Neurotherapeutic Research
Today, the 2016 Nobel Prize in the category of medicine or physiology was awarded to Yoshinori Ohsumi “for his discoveries of mechanisms for autophagy,” a fundamental process for degrading and recycling cellular components.
Category: GUMC Stories
-
Study: Cancer Drug Restores Brain Dopamine, Reduces Toxic Proteins in Parkinson, Dementia
MEDIA CONTACT:Karen Teberkm463@georgetown.edu WASHINGTON (July 11, 2016) — A small proof of concept study provides molecular evidence that an FDA-approved drug for leukemia significantly increased brain dopamine and reduced toxic proteins linked to disease progression in patients with Parkinson’s disease or dementia with Lewy bodies. Dopamine is the brain chemical (neurotransmitter) lost as a result […]
Category: News Release
-
Georgetown University and The Michael J. Fox Foundation for Parkinson’s Research Offer Fellowship in Regulatory Science
WASHINGTON and NEW YORK — Georgetown University Medical Center and The Michael J. Fox Foundation for Parkinson’s Research announce a fellowship in regulatory science that will promote postgraduate training in the Parkinson’s research field to optimize clinical trial design and support approval of novel therapies.
Category: News Release
-
Researchers Report First Therapy Appearing to Reverse Decline in Parkinson’s
OCTOBER 17, 2015 – An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small clinical trial, say researchers at Georgetown University Medical Center (GUMC). The drug, nilotinib (known as Tasigna® by Novartis) also led to statistically significant and encouraging changes in toxic […]
Category: GUMC Stories
-
Cancer Drug Improved Cognition and Motor Skills in Small Parkinson’s Clinical Trial
CHICAGO (Oct. 17, 2015) — An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small phase I clinical trial, report researchers at Georgetown University Medical Center (GUMC) in Washington. In addition, the drug, nilotinib (Tasigna® by Novartis), led to statistically significant […]
Category: News Release
-
Small Grants Supply the Research “Lifeblood” of Early Career Scientists
Three GUMC researchers describe the immeasurable impact of small grants from philanthropic organizations, foundations and the government on their work.
Category: GUMC Stories
-
Patients Drive Support Of Parkinson’s Fellowship Program
March 2, 2015 — Twelve years ago, Rick Schena, a United Airlines pilot, felt something amiss in the body he has always been so in tune with — the onset of tremors, some rigidity, and issues with processing vision. Six years ago he was diagnosed with Parkinson’s. This was devastating to the speed junkie who […]
Category: GUMC Stories
-
Cancer Drug Prevents Build-up of Toxic Brain Protein
WASHINGTON (May 10, 2013) — Researchers at Georgetown University Medical Center have used tiny doses of a leukemia drug to halt accumulation of toxic proteins linked to Parkinson’s disease in the brains of mice. This finding provides the basis to plan a clinical trial in humans to study the effects. They say their study, published […]
Category: News Release